ECSP066866A - Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas - Google Patents

Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas

Info

Publication number
ECSP066866A
ECSP066866A EC2006006866A ECSP066866A ECSP066866A EC SP066866 A ECSP066866 A EC SP066866A EC 2006006866 A EC2006006866 A EC 2006006866A EC SP066866 A ECSP066866 A EC SP066866A EC SP066866 A ECSP066866 A EC SP066866A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
related applications
dosage forms
compositions reference
methods
Prior art date
Application number
EC2006006866A
Other languages
English (en)
Inventor
Michel Bernatchez
Arwinder Nagi
Krishnendu Ghosh
Xiaohong Pan
Melissa Lin
Leonid Linberg
Ping Cai
Eric N C Browne
Mark Lankau
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066866A publication Critical patent/ECSP066866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere, por ejemplo, a nuevas formulaciones y métodos para la liberación de 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida, sales farmacéuticamente aceptables de la misma, compuestos estructuralmente relacionados, y/o metabolitos; así como al uso de estas formulaciones y métodos para tratar enfermedades
EC2006006866A 2004-03-19 2006-09-19 Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas ECSP066866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55462204P 2004-03-19 2004-03-19
US11/082,548 US20050215561A1 (en) 2004-03-19 2005-03-17 Pharmaceutical dosage forms and compositions

Publications (1)

Publication Number Publication Date
ECSP066866A true ECSP066866A (es) 2006-11-24

Family

ID=35094454

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006866A ECSP066866A (es) 2004-03-19 2006-09-19 Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas

Country Status (13)

Country Link
US (1) US20050215561A1 (es)
EP (1) EP1730139A2 (es)
JP (1) JP2007529551A (es)
KR (1) KR20070085090A (es)
AU (1) AU2005225435A1 (es)
BR (1) BRPI0508975A (es)
CA (1) CA2560243A1 (es)
EC (1) ECSP066866A (es)
IL (1) IL178067A0 (es)
MX (1) MXPA06010730A (es)
PE (1) PE20060125A1 (es)
TW (1) TW200539879A (es)
WO (1) WO2005092307A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AR058033A1 (es) * 2005-09-09 2008-01-23 Wyeth Corp Composiciones y formas de dosificacion farmaceuticas
CA2640569A1 (en) * 2006-01-26 2007-08-09 The University Of Rochester Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200831140A (en) * 2006-11-28 2008-08-01 Wyeth Corp Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
AR065376A1 (es) * 2007-02-16 2009-06-03 Wyeth Corp Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina - piperidina del receptor 5 ht1a que tienen disolucion instestinal mejorada
JP5819800B2 (ja) * 2012-10-31 2015-11-24 信越化学工業株式会社 高粘度ヒプロメロースを分散したコーティング液及び固形製剤の製造方法
JP6380922B2 (ja) * 2016-05-30 2018-08-29 大正製薬株式会社 チペピジンの経口用製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5635210A (en) * 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
ATE303795T1 (de) * 1998-12-16 2005-09-15 Aventis Pharma Inc In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2329122T3 (es) * 2002-03-12 2009-11-23 Wyeth Procedimiento para sintetizar n-aril piperazinas quirales.
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
JP4397693B2 (ja) * 2002-03-12 2010-01-13 ワイス Ｎ１−（２’−ピリジル）−１，２−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用
BR0308347A (pt) * 2002-03-12 2005-01-25 Wyeth Corp Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas

Also Published As

Publication number Publication date
EP1730139A2 (en) 2006-12-13
US20050215561A1 (en) 2005-09-29
WO2005092307A2 (en) 2005-10-06
AU2005225435A1 (en) 2005-10-06
MXPA06010730A (es) 2007-02-21
TW200539879A (en) 2005-12-16
IL178067A0 (en) 2006-12-31
WO2005092307A3 (en) 2006-01-19
JP2007529551A (ja) 2007-10-25
BRPI0508975A (pt) 2007-08-28
CA2560243A1 (en) 2005-10-06
KR20070085090A (ko) 2007-08-27
PE20060125A1 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
UY30327A1 (es) Nuevos compuestos ii
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
SV2008001369A (es) Benzimidazoles
BRPI0415424A (pt) processo para preparação de composto de aminocrotonila
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
CL2003002762A1 (es) Compuestos derivados de pirrolopirimidina o pirrolopiridina sustituidas por una amina ciclica, sus sales; composicion farmaceutica; y su uso para preparar un antagonista de los receptores de crf, para tratar enfermedades como depresion, ansiedad, alz
ECSP066866A (es) Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas
UY30460A1 (es) Compuestos terapéuticos
BRPI0513672A (pt) processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
GT200500309A (es) Derivados de sulfonilbencilimidazol
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
PA8514901A1 (es) Metabolitos agonistas/antagonistas de estrogeno
CR9800A (es) Formas y composiciones de dosificaciones farmaceuticas
DK1853232T3 (da) Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
CL2004000730A1 (es) Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so
AR052909A1 (es) Base cristalina del trans-1-((1r,3s)-6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina